Company Profile

Sidero Bioscience LLC
Profile last edited on: 11/30/22      CAGE: 55J48      UEI: ED5KEPFJKFY4

Business Identifier: Iron deficiency anemia (IDA)
Year Founded
2007
First Award
2016
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1214 Research Biulevard Suite 1011a
Hummelstown, PA 17036
   (412) 352-2498
   N/A
   www.siderobio.com
Location: Single
Congr. District: 10
County: Dauphin

Public Profile

Sidero Biosciences, LLC (Sidero) is a clinical stage biotechnology company advancing disruptive technologies targeting human digestive health. The firm's developed product - Siderosorb™ Medical Food platform - delivers beneficial proteins/complexes directly to the gastrointestinal (GI) tract to ameliorate human disease. With "Medical Foods" aot subject to the time and cost of drug development, the firm is ready for market launch BioFe™ Medical Food for Iron Deficiency provides a natural biologic form of iron that may not cause the GI upset seen with typical iron supplements. Saccharomyces cerevisiae has been used for over 9,000 years to make leavened bread, ferment alcoholic beverages, and as an excellent nutritional source. Sidero owns the patented Medical Food technology platform, Siderosorb™, utilizing Baker’s Yeast, Saccharomyces cerevisiae, to deliver therapeutic proteins/complexes directly to the GI tract in order to ameliorate human disease. Medical foods have a simplified and streamlined regulatory pathway allowing rapid and low-cost development, significantly accelerating market access and are routinely covered by medical insurance. Nutritional yeast contains all nine essential amino acids and is consumed by most world cultures, most popular as the Australian Vegemite, demonstrating that our delivery mechanism is generally regarded as safe, affordable, and in a readily acceptabl

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NIH $299,955
Project Title: Biofe Mechanism Of Action For The Treatment Of Iron Deficiency Anemia
2016 1 NIH $224,836
Project Title: Novel Medical Food for the Management of Iron Deficiency Anemia

Key People / Management

  Darren Wolfe -- President and CEO

  Michael Armstrong -- Chief Financial Officer, Member of the Board of Directors

  Thomas Clardy -- Executive Vice President

  James R Connor

  Debbie Firestine

  Robert E Harbaugh -- Chief Operating Officer, Member of the Board of Directors

  Ralph L Keil -- Senior Vice President of Research

  Silvan B Lutkewitte III -- Senior Vice President, Member of the Board of Director

Company News

There are no news available.